Abstract Number: 1140 • 2012 ACR/ARHP Annual Meeting
Response to Adalimumab in 40 Patients with refractory juvenile Idiopathic Arthritis-Associated Uveitis. A Multicenter Study
Background/Purpose: To assess the efficacy and safety of treatment with adalimumab therapy in patients with refractory Juvenile Idiopathic Arthritis (JIA)-associated uveitis. Methods: Multicenter study on…Abstract Number: 1141 • 2012 ACR/ARHP Annual Meeting
Safety of Celecoxib and Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Juvenile Idiopathic Arthritis
Background/Purpose: Celecoxib, a selective COX-2 inhibitor, was approved by the FDA for the treatment of the signs and symptoms of JIA in children aged 2-17…Abstract Number: 1142 • 2012 ACR/ARHP Annual Meeting
Efficacy of Biologic Agents in Juvenile Idiopathic Arthritis: A Systematic Review Using Indirect Comparisons
Background/Purpose: During the last decade the availability of biologic agents for the treatment of juvenile idiopathic arthritis (JIA) increased substantially. Because direct head-to-head trials comparing…Abstract Number: 1143 • 2012 ACR/ARHP Annual Meeting
Tocilizumab Therapy in Children with Systemic Onset Juvenile Idiopathic Arthritis. Russian Experience
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is classified as an acquired autoinflammatory disease. The interleukin-1 and interleukin-6 play a pivotal role in pathogenesis of this…Abstract Number: 1144 • 2012 ACR/ARHP Annual Meeting
Phenotypic Characterization of Childhood Onset Rheumatoid Arthritis
Background/Purpose: Rheumatoid Factor positive polyarthritis (RF+ poly) is the JIA subtype that resembles adult seropositive RA. However, the ILAR classification criteria for RF+ polyarthritis do…Abstract Number: 1145 • 2012 ACR/ARHP Annual Meeting
Use of Non-Etanercept Biologics in Children with Juvenile Idiopathic Arthritis: Results From the Biologics for Children with Rheumatic Diseases Study
Background/Purpose: The management of juvenile idiopathic arthritis (JIA) has been revolutionised by the introduction of biologic therapy, although the majority remain unlicensed for children. Until…Abstract Number: 1146 • 2012 ACR/ARHP Annual Meeting
Choice of Systemic JIA Treatment Among Childhood Arthritis and Rheumatology Research Alliance (CARRA) Rheumatologists
Background/Purpose: Despite recent advances in identifying effective treatments for systemic Juvenile Idiopathic Arthritis (sJIA), many pediatric rheumatologists continue to use corticosteroids and methotrexate. The Childhood…Abstract Number: 1147 • 2012 ACR/ARHP Annual Meeting
Definition of Improvement Thresholds in Juvenile Idiopathic Arthritis Using the JADAS
Definition of improvement thresholds in juvenile idiopathic arthritis (JIA) using the JADAS Background/Purpose: Evaluation of disease activity in JIA is fundamental in clinical assessment. The…Abstract Number: 1148 • 2012 ACR/ARHP Annual Meeting
Adalimumab – Effective Control under Refractory JIA Associated Uveitis
Background/Purpose: Treatment of juvenile idiopathic arthritis (JIA)–associated uveitis is one of the serious problems of paediatric rheumatology. JIA associated uveitis often is refractory to MTX,…Abstract Number: 1149 • 2012 ACR/ARHP Annual Meeting
Long-Term Safety of Etanercept in Patients with Juvenile Idiopathic Arthritis (JIA)
Background/Purpose: Etanercept (Eta) has been the most frequently used biologic drug in patients with JIA. In Germany, about one in three patients with polyarticular JIA…Abstract Number: 1150 • 2012 ACR/ARHP Annual Meeting
Adverse Events in Juvenile Idiopathic Arthritis: Results From the Enhanced Drug Safety Surveillance (EDSS) Pilot Project
Background/Purpose: There are few data available regarding the rates of serious and important medical events (SAEs and IMEs) for most of the medications used to…Abstract Number: 1151 • 2012 ACR/ARHP Annual Meeting
Low-Dose Methotrexate and the Selective Accumulation of Intracellular Aminoimidazolecarboxamide Ribotide
Background/Purpose: Current evidence suggests that the anti-folate methotrexate (MTX) mediates its anti-inflammatory effects through inhibition of the purine synthesis pathway causing the accumulation of…Abstract Number: 1152 • 2012 ACR/ARHP Annual Meeting
Improvement in Health-Related Quality of Life for Children with Juvenile Ideopathic Arthritis After Start of Treatment with Etanercept
Background/Purpose: The concept of Health-related quality of life (HrQoL) has been widely accepted as a burden of disease measure in recent years. The improvement in…Abstract Number: 1153 • 2012 ACR/ARHP Annual Meeting
Perceived Health-Related Quality of Life and Its Determining Factors in Children with Recent-Onset JIA
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease and a major cause of chronic disability in children aged below 16 years.…Abstract Number: 1154 • 2012 ACR/ARHP Annual Meeting
Impact of FokI VDR and TNFalpha–308 Polymorphism On Disease Severity and Long Term Outcome in JIA Patients On Anti-TNF Treatment
Background/Purpose: Genetic contribution of SNP (single nucleotide polymorphism) of TNFα–308 promoter and FoxI for VDR (vitamin D receptor) polymorphism on disease severity and outcome in…